Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
McKesson
Cantor Fitzgerald
Argus Health
AstraZeneca
Harvard Business School
Johnson and Johnson
US Department of Justice
Healthtrust

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,528,486

« Back to Dashboard

Title: Peptide agonists of GLP-1 activity
Abstract:The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.
Inventor(s): Larsen; Bjarne Due (Br.o slashed.nsh.o slashed.j, DK), Mikkelsen; Jens Damsgaard (Lyngby, DK), Neve; S.o slashed.ren (Lyngby, DK)
Assignee: Zealand Pharma A/S (Glostrup, DK)
Filing Date:Jul 12, 2000
Application Number:09/614,847
Claims:1. A peptide consisting of any one of the following sequences: a) H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala- Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro -Ser-(Lys).sub.6 -NH.sub.2 (des-Pro.sup.36 -exendin-4(1-39)-Lys.sub.6 -NH.sub.2) (SEQ ID NO:93), b) H-Lys.sub.6 -His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-V al-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro- Ser-(Lys).sub.6 -NH.sub.2 (H-Lys.sub.6 -des Pro.sup.36 exendin-4(1-39)-Lys.sub.6 -NH.sub.2) (SEQ ID NO: 149), c) H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala- Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala -Ser-NH.sub.2 (H-des Pro.sup.36,Pro.sup.37,Pro.sup.38 exendin-4(1-39)-NH.sub.2) (SEQ ID NO: 132), d) H-Lys-Lys-Lys-Lys-Lys-Lys-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys- Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro -Ser-Ser-Gly-Ala-Ser-NH.sub.2 (H-(Lys).sub.6 -des Pro.sup.36,Pro.sup.37,Pro.sup.38 exendin-4(1-39)-NH.sub.2), (SEQ ID NO: 134), e) H-Asn-Glu-Glu-Glu-Glu-Glu-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys- Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro -Ser-Ser-Gly-Ala-Ser-NH.sub.2 (H-Asn-(Glu).sub.5 -des Pro.sup.36,Pro.sup.37, Pro.sup.38 exendin-4(1-39)-NH.sup.2) (SEQ ID NO: 137), f) H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala- Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-(Ly s).sub.6 -NH.sub.2 (des Pro.sup.36, Pro.sup.37,Pro.sup.38 exendin-4(1-39)-(Lys).sub.6 -NH.sub.2) (SEQ ID NO: 133), g) H-(Lys).sub.6 -His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-V al-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Ser-(Lys ).sub.6 -NH.sub.2 (H-(Lys).sub.6 -des Pro.sup.36,Pro.sup.37,Pro.sup.38 exendin-4(1-39)-(Lys).sub.6 -NH.sub.2) (SEQ ID NO: 135), h) H-Asp-Glu-Glu-Glu-Glu-Glu-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys- Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro -Ser-Ser-Gly-Ala-Ser-(Lys).sub.6 -NH.sub.2 (H-Asn-(Glu).sub.5 -des Pro.sup.36,Pro.sup.37,Pro.sup.38 exendin-4(1-39)-(Lys).sub.6 -NH.sub.2) (SEQ ID NO: 136); or a pharmaceutically acceptable salt thereof.

2. A composition comprising the peptide of claim 1 and a physiologically acceptable carrier.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chubb
Fuji
Daiichi Sankyo
Fish and Richardson
US Department of Justice
Julphar
Farmers Insurance
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.